DiaSorin (OTCMKTS:DSRLF) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of DiaSorin (OTCMKTS:DSRLF) from a sell rating to a hold rating in a research note released on Thursday morning, Zacks.com reports.

According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “

Shares of DSRLF opened at $114.75 on Thursday. DiaSorin has a 12-month low of $80.10 and a 12-month high of $114.75. The firm’s 50-day moving average price is $113.73.

DiaSorin Company Profile

DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on DiaSorin (DSRLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.